Company intelligence / Profile preview
Istesso
United Kingdomistesso.co.uk ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Istesso develops first-in-class small molecule drugs that harness the body’s natural adaptive repair mechanisms to treat chronic diseases by repairing damaged tissue rather than just controlling symptoms. Their lead candidate, leramistat, has shown promising results in repairing bone/joint damage in RA without immunosuppression and also targets lung scarring in IPF. Leramistat has received FDA Fast Track and Orphan Drug Designation for IPF. The company’s approach represents a novel paradigm shift from disease management to programmed disease resolution.
- Therapeutic areas
- OtherImmunologyPulmonologyRheumatology
- Modalities
- Small molecules (noted as "once-daily pill" and drug-like compounds)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on Istesso.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Istesso.